SCHEMBL20294380

SCHEMBL20294380

NC(=O)c1ccc(-c2cccc(-c3ccccc3)c2Cl)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNA5 P22460 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ CHEK2 O96017 3/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.46
▸ SIRT6 Q8N6T7 1/20 0.45
▸ BCAT2 O15382 1/20 0.45
▸ SCN9A Q15858 1/20 0.44
▸ MAP4K4 O95819 4/20 0.44
▸ HIF1A Q16665 4/20 0.42
▸ PRF1 P14222 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ PARP1 P09874 1/20 0.40
▸ CDC7 O00311 1/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ MAPK13 O15264 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ DYRK3 O43781 1/20 0.40
▸ ROCK2 O75116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4502688 0.86 SCN9A (0.54) SIRT6SCN9AHIF1APRF1KMT2A
SCHEMBL27925869 0.83 SCN9A (0.49) CHEK2SIRT6SCN9AMAP4K4HIF1A
SCHEMBL2927582 0.82 HIF1A (0.53) CHEK2MKNK1HIF1AKMT2APARP1
SCHEMBL20294436 0.77 MAP4K4 (0.41) MAP4K4CSNK2A1
SCHEMBL4768283 0.76 KMT2A (0.57) MKNK1SIRT6MAP4K4PRF1KMT2A
SCHEMBL4280915 0.76 SIRT6 (0.41) KCNA5KCNH2CHEK2MKNK1SIRT6
SCHEMBL9930222 0.75 CNR2 (0.47) CHEK2MKNK1SIRT6BCAT2SCN9A
SCHEMBL6237302 0.73 ALOX5AP (0.53) PRF1
SCHEMBL27922260 0.72 MAP4K4 (0.60) CHEK2MKNK1MAP4K4HIF1APRF1
SCHEMBL26556671 0.72 CYP2A6 (0.62) BCAT2PLK4MAPK1MAPK9LIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 — — US disclosed
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 — — US disclosed
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-07-20 — — US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed
WO-2018119263-A1 HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS INCYTE CORPORATION (US) 2018-06-28 — — WO disclosed
WO-2018119263-A1 HETEROCYCLIC COMPOUNDS DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS INCYTE CORPORATION (US) 2018-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180177784-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 KCNA5 4557/4885KCNH2 4127/4885CHEK2 598/4885
US-20230226062-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 KCNA5 4557/4885KCNH2 4127/4885CHEK2 598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback